ONDINE BIOMEDICAL INC.CDI (VF5) - Total Liabilities
Based on the latest financial reports, ONDINE BIOMEDICAL INC.CDI (VF5) has total liabilities worth €5.95 Million EUR (≈ $6.95 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of ONDINE BIOMEDICAL INC.CDI to track the company's year-over-year net asset growth rate.
ONDINE BIOMEDICAL INC.CDI - Total Liabilities Trend (2021–2024)
This chart illustrates how ONDINE BIOMEDICAL INC.CDI's total liabilities have evolved over time, based on quarterly financial data.
ONDINE BIOMEDICAL INC.CDI Competitors by Total Liabilities
The table below lists competitors of ONDINE BIOMEDICAL INC.CDI ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aureus Greenway Holdings Inc.
NASDAQ:PUSA
|
USA | $1.54 Million |
|
Hainan Airlines Co Ltd B
SHG:900945
|
China | $143.12 Billion |
|
Shanghai Lingang Holdings Co Ltd B
SHG:900928
|
China | $57.66 Billion |
|
Indorama Synthetics Tbk
JK:INDR
|
Indonesia | Rp403.10 Million |
|
Anfield Resources Inc
V:AEC
|
Canada | CA$36.89 Million |
|
Magadh Sugar & Energy Limited
NSE:MAGADSUGAR
|
India | Rs4.18 Billion |
|
Powertech Industrial Co Ltd
TW:3296
|
Taiwan | NT$879.20 Million |
|
Definitive Healthcare Corp
NASDAQ:DH
|
USA | $356.50 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down ONDINE BIOMEDICAL INC.CDI's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see VF5 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.86 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ONDINE BIOMEDICAL INC.CDI's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ONDINE BIOMEDICAL INC.CDI (2021–2024)
The table below shows the annual total liabilities of ONDINE BIOMEDICAL INC.CDI from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €5.95 Million ≈ $6.95 Million |
+62.92% |
| 2023-12-31 | €3.65 Million ≈ $4.27 Million |
-25.91% |
| 2022-12-31 | €4.92 Million ≈ $5.76 Million |
+9.86% |
| 2021-12-31 | €4.48 Million ≈ $5.24 Million |
-- |
About ONDINE BIOMEDICAL INC.CDI
Ondine Biomedical Inc., a life-sciences company, engages in the development and commercialization of antimicrobial therapies in Canada and internationally. Its primary product is Steriwave, which enables rapid elimination of pathogens associated with healthcare-associated infections. In addition, the company offers a pipeline of products for various indications, including burns, ventilator tube, … Read more